Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases

Breast Journal

Volumn 19, Issue 1, 2013, Pages 96-99

  Ang, Celina ^a   Jhaveri, Komal ^b   Patel, Dina ^a   Gewirtz, Alexandra ^a   Seidman, Andrew ^b   Kemeny, Nancy ^a  

^a Gastrointestinal Oncology Service   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

breast cancer; hepatic arterial infusion chemotherapy; liver metastases

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EXEMESTANE; FLOXURIDINE; FULVESTRANT; GEMCITABINE; IRINOTECAN; IXABEPILONE; LAPATINIB; LIVER ENZYME; MITOMYCIN; NAVELBINE; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER LIVER METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEASIBILITY STUDY; FEMALE; HEPATIC ARTERY; HUMAN; LIVER ENZYME BLOOD LEVEL; LIVER METASTASIS; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREATITIS; PROGRESSION FREE SURVIVAL; STOMACH VARICES BLEEDING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; FLOXURIDINE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84872274742     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12050     Document Type: Article

References (29)

1. Chia SK, Speers CH, D'Yachkova Y, et al,. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-9.
2. Largillier R, Ferrero JM, Doyen J, et al,. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 2008; 19: 2012-9.
3. Hagemeister FB Jr, Buzdar AU, Luna MA, Blumenschein GR,. Causes of death in breast cancer. A clinicopathologic study. Cancer. 1980; 46: 162-7.
4. Chua TC, Saxena A, Liauw W, Chu F, Morris DL., Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011; 47: 2282-90.
5. Kemeny N,. In defense of hepatic arterial infusion for hepatic metastasis of colon cancer. J Natl Compr Cancer Netw 2010; 8: 507-9.
6. Kemeny N, Fata F,. Hepatic-arterial chemotherapy. Lancet Oncol 2001; 2: 418-28.
7. Fraschini G, Charsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN,. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol 1988; 11: 34-8.
8. Tokura H, Ikeda T, Masamura S, et al,. Clinical experience of intra-arterial chemotherapy for liver metastases of breast cancer patients. Gan To Kagaku Ryoho 2001; 28: 1780-2.
9. Schneebaum S, Walker MJ, Young D, Farrar WB, Minton JP,. The regional treatment of liver metastases from breast cancer. J Surg Oncol 1994; 55: 26-32.
10. Ikeda T, Adachi I, Takashima S, et al,. A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. Jpn J Clin Oncol 1999; 29: 23-7.
11. Cortes J, O'Shaughnessy J, Loesch D, et al,. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011; 377: 914-23.
12. Sutanto-Ward E, Arisawa Y, Tremiterra S, Sigurdson ER,. Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations. Ann Surg Oncol 1996; 3: 36-43.
13. Borner M, Laffer U, Ludwig C, et al,. Effectiveness and low toxicity of hepatic arterial infusion with fluorouracil and mitomycin-c for metastatic colorectal cancer confined to the liver. Ann Oncol 1990; 1: 227-8.
14. Creech RH, Catalano RB, Shah MK, Dayal H,. An effective low dose mitomycin regimen for hormonal and chemotherapy refractory patients with metastatic breast cancer. Cancer 1983; 51: 1034-40.
15. Kemeny N, Gonen M, Sullivan D, et al,. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687-95.
16. Perez EA, Hillman DW, Mailliard JA, et al,. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane or both. J Clin Oncol 2004; 22: 2849-55.
17. Saphner T, Trist-Robertson S, Li H, Holzman P,. The association of non-alcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009; 115: 3189-95.
18. Saif MW, Shahrokni A, Cornfeld D,. Gemcitabine induced liver fibrosis in a patient with pancreatic cancer. JOP 2007; 8: 460-7.
19. Kemeny N, Seiter K, Niedzwiecki D, et al,. A randomized trial of intrahepatic infusion of fluorodeoxyuridine (FUDR) with dexamethasone versus FUDR alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-34.
20. Kemeny N, Gonen M, Sullivan D, et al,. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687-95.
21. Ito K, Ito H, Kemeny NE, et al,. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal liver metastases: incidence, clinical features and risk factors. Ann Surg Oncol 2012; 19: 1609-17.
22. Fumoleau P,. Treatment of patients with liver metastases. Anticancer Drugs 1996; 7 (Suppl. 2): 21-3.
23. Goldstein LJ, Galski H, Fojo A, et al,. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
24. Er O, Frye DK, Kau SW, et al,. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008; 14 (1): 62-8.
25. Ribatti D, Mangialardi G, Vacca A,. Stephen Paget and the "seed and soil" theory of metastatic dissemination. Clin Exp Med 2006; 6: 145-9.
26. Aft R,. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data. Clin Adv Hematol Oncol 2011; 9: 194-205.
27. Viadana E, Bross IDJ, Pickren JW,. An autopsy study of some routes of dissemination of the breast. Br J Cancer 1973; 27: 336-40.
28. Bathe OF, Kaklamanos IG, Moffat FL, Boggs J, Franceschi D, Livingstone AS,. Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol 1999; 8: 35-42.
29. Sanz R, Argues R, Stresing V, et al,. Functional pathways shared by liver and lung metastases: a mitochondrial chaperone machine is up-regulated in soft-tissue breast cancer metastasis. Clin Exp Metastasis 2007; 24: 673-83.